BioLineRx (BLRX) announced new data from a phase IIa study on its pipeline candidate BL-7040. BioLineRx is developing BL-7040 for the treatment of inflammatory bowel disease (:IBD). Results revealed significant improvement in disease measurements in biopsies taken from IBD patients treated with BL-7040. The histological and biochemical analyses of inflammation indicators back the initial positive results of the study, reported in April 2013. The initial results revealed that BL-7040 was safe and effective in treating patients suffering from ulcerative colitis which is a form of IBD.
In the phase IIa study, Biopsies taken from participants before and after treatment were collected and randomly assigned to either a histological evaluation or to an assessment for levels of cytokines, considered as pro-inflammatory bio-markers. Histological evaluation in patients treated with BL-7040 revealed significant reduction in neutrophil levels.
The level of the pro-inflammatory cytokine - interleukin 6 (IL-6) is an additional measure of IBD severity. Significant reduction was also seen in IL-6 in patients treated with BL-7040. Data also showed clinical improvement in patients with reduced cytokine levels.
We note that in Jun 2011, BioLineRx entered into a licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. for BL-7040.
BioLineRx mentioned in its press release that sales generated from existing IBD drugs in the U.S. were $5.6 billion in 2012. Companies like Johnson & Johnson (JNJ) and Shire (SHPG) also have a presence in the IBD market.
BioLineRx, a biopharmaceutical company, carries a Zacks Rank #4 (Sell). Investors interested in the biopharmaceutical industry may consider Actelion Ltd. (ALIOF) which carries a Zacks Rank #1 (Strong Buy).Read the Full Research Report on BLRX
Read the Full Research Report on ALIOF
Read the Full Research Report on JNJ
Read the Full Research Report on SHPG
Zacks Investment Research
- Health Care Industry
- inflammatory bowel disease